Shanghai, 2020.06.15. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies announced today that it has submitted an Investigational New Drug (IND) application to the Center of Drug Evaluation (CDE) in Beijing to support the initiation of a Phase I clinical trial of ES102 in China.
ES102 is a hexavalent OX40 agonistic antibody with a unique “first-in-class” design. The special design of ES102 allows for efficient OX40 agonism even in the absence of exogenous cross-linking. ES102 induces much strong immune activation compared to tetrameric or conventional bivalent OX40 antibodies, it has demonstrated impressive single agent anti-tumor efficacy and great synergy with anti-PD1/PD-L1 agents in preclinical models. OX40, also known as CD134, is a member of the tumor necrosis factor (TNF) receptor family and is an important co-stimulator of T cell responses. Typically for TNF receptor family members, 3 molecules of OX40 bind to the trimeric OX40 ligand protein, activating downstream NF-κB, PI3K, and AKT pathways, which ultimately leads to increased cytokine production and is associated with enhanced T-cell expansion, differentiation, and the generation of long-lived memory T-cells.
Elpiscience is a clinical-stage biopharmaceutical company focusing on cancer immunotherapy. The company is committed to leading the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpiscience has a pipeline of more than 10 innovative molecules with its most advanced asset, ES101, already in clinical trials. Elpiscience’s innovations cover a wide range of immunology targets with a focus on innate immunity and tumor microenvironment. For more information please visit: http://www.elpiscience.com.